The evolution of esophageal cancer between in Mureș county Coordinator: Dr. Radu Florin Demian First author: Pál Hunor
Background – Worldwide and EU Worldwide (8th most common cancer) ,645 cases ,000 cases Rate of incidence - highest in South Africa ( ♂, ♀ ) -lowest in West of Africa ( ♂ ) and South Europe ( ♀ ). -83% in less developed regions of the world - 5 th most common cancer in men In the EU, 2008: - highest rates: UK, 14 ( ♂ ) and 5 ( ♀ )cases/100,000 pers. - lowest rates: Cyprus ( ♂ ) and Greece ( ♀ ) (1 case and less than 1 case/100,000 pers.)
Background – Romania (rate per 100,000 pers.) incidence 3 -mortality 1, incidence 2,32 -mortality 2, incidence 3,9 -mortality 3,5 Mureș county ( citizens) - lowest incidence in 2012, 0,3113% - highest incidence in 2013, 0,8751%
About Two major types - squamous cell carcinoma (SCC) - adenocarcinoma (AC) - < 1-2 % Sarcomas, small cell carcinomas and other types of cancer A. SCC - middle or upper 1/3 B. AC in the lower 1/3 or junction of the esophagus and stomach One of the least studied and deadliest cancers worldwide Extremely aggressive nature, poor survival rate.
Major aethiological factors Smoking Alcool consumption Malnutrition ( beta-carotene, B-vitamins, vitamin C and E, selenium) Barrett’s oesophagus
Aim, material and methods Follow the evolution of esophageal cancer in Mureș county between , by incidence, distribution by sexes, place of provenance, by group of ages, survivals and cytostatic threatment schemes. Retrospective study on 66 pacients (55 male, 11 female) - threated in the Oncology Clinics of Targu Mureș.
Distribution by sexes Distribution by sexes
Distribution by place of provenance
Distribution by group of ages
Survival curves
Cytostatic threatment 53 cycles, 11 schemes Cisplatin8 Carboplatin6 Gemcitabin7 Oxaliplatin2 5-FU3 Carboplatin + Docetaxel11 Carboplatin+ Paclitaxel7 Gemcitabin + Carboplatin4 Capecitabin + Cisplatin2 Epirubicin + Cisplatin2 Epirubicin ă + Oxaliplatin ă 1
Conclusions Low incidence More frequent at males More frequent at rural areas Most of cases are between ages (31/66), no cases below 40 Simultaneous decrease of the age group and increase of Two year survival is low Managing major risk factors (especially smoking and alcool consumption) should reduce the incidence, or at least prevent appearing at younger ages (41-50).
Thanks for the attention!